Alkermes Plc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Alkermes Plc 公司

Alkermes plc 是一家总部位于爱尔兰的生物制药公司，致力于开发神经科学领域的药物。该公司拥有一系列用于治疗酒精依赖、阿片类药物依赖、精神分裂症和 I 型双相情感障碍的商业产品，以及一系列用于治疗神经系统疾病的临床和临床前候选药物。该公司专注于 LYBALVI、Aristada/Aristada INITIO 和 VIVITROL 等商业产品，并推进专注于神经系统疾病的管线项目的开发。LYBALVI 是一种每日一次的口服非典型抗精神病药物，用于治疗患有精神分裂症的成年人和患有 I 型双相情感障碍的成年人，作为维持性单一疗法或用于躁狂或混合发作的急性治疗，作为单一疗法或锂或丙戊酸的辅助疗法。Aristada 是一种缓释型肌肉注射混悬液，用于治疗精神分裂症。该公司在俄亥俄州威尔明顿设有一家制造工厂。

公司简介

公司代码ALKS

公司名称Alkermes Plc

上市日期Jul 16, 1991

CEOMr. Richard F. Pops

员工数量1800

证券类型Ordinary Share

年结日Jul 16

公司地址Connaught House

城市DUBLIN

上市交易所NASDAQ Global Select Consolidated

国家Ireland

邮编D04 C5Y6

电话35317728000

网址https://www.alkermes.com/

公司代码ALKS

上市日期Jul 16, 1991

CEOMr. Richard F. Pops

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.29M

--

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

205.37K

+0.55%

Mr. Shane M. Cooke

Independent Director

103.74K

+3.84%

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

77.74K

--

Mr. Brian P. Mckeon

Independent Director

43.87K

+16.12%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

+24.36%

Dr. Cato T. Laurencin, M.D., Ph.D.

Independent Director

29.10K

+26.46%

Dr. Christopher I. Wright, M.D., Ph.D.

Independent Director

23.01K

+12.23%

Ms. Nancy S. Lurker

Independent Director

10.71K

+131.91%

Dr. Nancy L. Snyderman, M.D.

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.29M

--

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

205.37K

+0.55%

Mr. Shane M. Cooke

Independent Director

103.74K

+3.84%

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

77.74K

--

Mr. Brian P. Mckeon

Independent Director

43.87K

+16.12%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

+24.36%

收入明细

单位: USD更新时间: 7月6日周日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

VIVITROL

101.00M

32.95%

ARISTADA

73.47M

23.97%

LYBALVI

70.02M

22.84%

Royalty Revenue - VUMERITY

21.86M

7.13%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

17.75M

5.79%

其他

22.41M

7.31%

暂无数据

业务

地区

业务USD

名称

营收

占比

VIVITROL

101.00M

32.95%

ARISTADA

73.47M

23.97%

LYBALVI

70.02M

22.84%

Royalty Revenue - VUMERITY

21.86M

7.13%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

17.75M

5.79%

其他

22.41M

7.31%

股东统计

更新时间: 8月16日周六

持股股东

股东类型

持股股东

占比

BlackRock Institutional Trust Company, N.A.

14.37%

The Vanguard Group, Inc.

11.18%

T. Rowe Price Associates, Inc.

5.97%

State Street Global Advisors (US)

4.97%

Baker Bros. Advisors LP

3.88%

其他

59.62%

持股股东

占比

BlackRock Institutional Trust Company, N.A.

14.37%

The Vanguard Group, Inc.

11.18%

T. Rowe Price Associates, Inc.

5.97%

State Street Global Advisors (US)

4.97%

Baker Bros. Advisors LP

3.88%

其他

59.62%

股东类型

持股股东

占比

Investment Advisor

53.95%

Investment Advisor/Hedge Fund

29.52%

Hedge Fund

14.46%

Research Firm

3.18%

Pension Fund

1.82%

Individual Investor

1.66%

Sovereign Wealth Fund

1.18%

Private Equity

0.61%

Bank and Trust

0.44%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

770

179.09M

108.49%

-26.85M

2025Q1

781

180.42M

109.41%

-27.12M

2024Q4

750

175.04M

107.61%

-39.68M

2024Q3

727

186.93M

115.42%

-33.14M

2024Q2

708

187.79M

113.20%

-24.77M

2024Q1

682

184.21M

108.96%

-28.40M

2023Q4

653

184.12M

110.36%

-5.13M

2023Q3

620

171.53M

102.92%

-4.71M

2023Q2

610

167.10M

100.38%

-17.86M

2023Q1

604

167.47M

100.88%

-20.36M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

BlackRock Institutional Trust Company, N.A.

23.98M

14.54%

-541.92K

-2.21%

Mar 31, 2025

The Vanguard Group, Inc.

18.16M

11.01%

-283.51K

-1.54%

Mar 31, 2025

T. Rowe Price Associates, Inc.

11.62M

7.05%

-472.94K

-3.91%

Mar 31, 2025

State Street Global Advisors (US)

8.02M

4.87%

-792.30K

-8.99%

Mar 31, 2025

Baker Bros. Advisors LP

4.48M

2.72%

+301.53K

+7.21%

Mar 31, 2025

Renaissance Technologies LLC

5.74M

3.48%

+260.10K

+4.75%

Mar 31, 2025

RTW Investments L.P.

6.88M

4.17%

-673.14K

-8.91%

Mar 31, 2025

Geode Capital Management, L.L.C.

3.94M

2.39%

+121.05K

+3.17%

Mar 31, 2025

JP Morgan Asset Management

4.13M

2.5%

+3.88M

+1560.15%

Mar 31, 2025

American Century Investment Management, Inc.

3.47M

2.1%

+14.97K

+0.43%

Mar 31, 2025

持股ETF

更新时间: 8月6日周三

机构名称

占比

AdvisorShares Psychedelics ETF

6.14%

iShares Neuroscience and Healthcare ETF

3.66%

ALPS Medical Breakthroughs ETF

3.19%

First Trust NYSE Arca Biotechnology Index Fund

3.01%

Invesco S&P SmallCap Health Care ETF

2.95%

Tema Neuroscience and Mental Health ETF

1.62%

Knowledge Leaders Developed World ETF

1.55%

Langar Global HealthTech ETF

1.39%

Invesco S&P SmallCap Quality ETF

1.34%

Janus Henderson Small Cap Growth Alpha ETF

1.25%

AdvisorShares Psychedelics ETF

占比6.14%

iShares Neuroscience and Healthcare ETF

占比3.66%

ALPS Medical Breakthroughs ETF

占比3.19%

First Trust NYSE Arca Biotechnology Index Fund

占比3.01%

Invesco S&P SmallCap Health Care ETF

占比2.95%

Tema Neuroscience and Mental Health ETF

占比1.62%

Knowledge Leaders Developed World ETF

占比1.55%

Langar Global HealthTech ETF

占比1.39%

Invesco S&P SmallCap Quality ETF

占比1.34%

Janus Henderson Small Cap Growth Alpha ETF

占比1.25%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Alkermes Plc

28.380USD

Alkermes Plc

28.380

概览

公司

财务

分析